Topic: rheumatoid arthritis
Gilead emerged from a meeting with the FDA this summer confident it would file for approval in the U.S. by the end of 2019.
The days without biosimilar competition are numbered for AbbVie’s Humira in the U.S.—and that’s where rheumatoid arthritis drug Rinvoq comes in.
The companies said the 52-week phase 3 data for JAK1 inhibitor filgotinib in rheumatoid arthritis are consistent with earlier readouts.
The submission moves Gilead a step closer to selling the Galapagos-partnered drug to rheumatoid arthritis patients in the country.
The VC plans to pump $150 million into biotechs that are working to extend use of advanced therapies to major diseases such as diabetes.
The investment extends Abivax’s cash runway out to the middle of 2020, buying the biotech time to find a partner for ABX464.
Gilead and Galapagos have notched another series of late-stage wins for their JAK inhibitor filgotinib.
The Big Pharma has culled a dual amylin calcitonin receptor agonist, a BTK inhibitor and a urocortin-2 peptide.
Olumiant eventually nabbed the nod it needed to take on Pfizer’s Xeljanz, the only other drug in its class approved for rheumatoid arthritis, but with caveats.
Capitalizing on a process the body uses to eliminate overly aggressive T cells could be a new way to treat autoimmune diseases.